Third-Generation Testing Platform with Enhanced Features and Benefits to
Premier at AACC
SAN DIEGO, July 24 /PRNewswire-FirstCall/ -- Biosite(R) Incorporated
(Nasdaq: BSTE) today announced the premiere of its third-generation testing
platform, the Triage(R) MeterPro(TM), at the American Association for
Clinical Chemistry 2006 Annual Meeting, to be held in Chicago from July 23
through 27, 2006. The Triage MeterPro combines Biosite's rapid, easy-to-use
technology with a more convenient user interface. The Triage MeterPro's
user-friendly features will make testing even easier to perform, while
maintaining the high quality and performance standards of the existing
Triage Meter platform.
(Photo: http://www.newscom.com/cgi-bin/prnh/20060724/LAM077 )
Enhancements to the Triage MeterPro include an alphanumeric keypad, 75
percent larger display, backlighting and faster printing. The Triage Meters
also feature "Test Select(TM)," which gives healthcare providers the
flexibility to customize test menus based on physician preference or
patient presentation when using Triage Test Panels with multiple analytes.
This allows customers to use the same multi-analyte Triage Panel but choose
which assays to run at the time of testing.
The Triage MeterPro is a portable, rapid testing platform designed to
provide rapid, quantitative or qualitative results for immunoassays using
urine, whole-blood or plasma and features comprehensive built-in quality
control capabilities. Biosite's current and future Triage tests will
continue to be compatible with the Triage MeterPro and the Triage
MeterPlus. The Triage MeterPro is now available in the United States and
will launch internationally in the second half of 2006.
For information on the Triage MeterPro or how to order Biosite
products, please contact Biosite at (888) BIOSITE (246-7483), or email:
custservice@biosite.com.
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis. The
Company's products contribute to improvements in medical care by aiding
physicians in the diagnosis of critical diseases and health conditions.
Biosite's Triage rapid diagnostics are used in approximately 50 percent of
U.S. hospitals and in more than 50 international markets. Information on
Biosite can be found at http://www.biosite.com.
Except for the historical information presented herein, matters
discussed in this press release are forward-looking statements that involve
risks and uncertainties that could cause actual results to differ
materially from any future results, performance or achievements expressed
or implied by such statements. Statements that are not historical facts,
including but not limited to statements that are preceded by, followed by,
or that include the words "will"; "believes"; "should"; "intends";
"anticipates"; "plans"; "expects"; "estimates"; or similar statements are
forward-looking statements. Forward looking statements include statements
about the potential benefits of the Triage MeterPro, and the commencement
of marketing, education and sales of this third-generation product. Risks
and uncertainties include risks regarding the discovery and product
development process generally, risks associated with the commencement of
manufacturing the Triage MeterPro on a commercial scale and risks that the
Triage MeterPro may not be commercially successful. Other risks and
uncertainties that may impact the Company's business generally include
risks associated with the introduction of competitive products from
companies with greater capital and resources, expansion or development of a
direct sales effort in domestic and international markets, manufacturing
constraints, backlog, delays or inefficiencies, shipment problems,
regulatory changes and the other risks detailed in the Company's most
recent Annual Report on Form 10-K and other SEC filings. The Company
disclaims, however, any intent or obligation to update these
forward-looking statements. Copies of the Company's public disclosure
filings are available from the Investor Relations department.
Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered
trademarks of Biosite Incorporated. The Company's logo, MeterPro and Test
Select are trademarks of Biosite Incorporated.
SOURCE Biosite Incorporated
back to top
Related links: http://www.biosite.com
Photo Notes: NewsCom: http://www.newscom.com/cgi-bin/prnh/20060724/LAM077 AP Archive: http://photoarchive.ap.org PRN Photo Desk, photodesk@prnewswire.com
http://www.prnewswire.com/comp/116737.html /
CONTACT: Nadine Padilla, VP, Corporate & Investor Relations, +1-858-805-2820, npadilla@biosite.com, or Susan Schotthoefer, Sr. Corporate Communications Specialist, +1-858-805-2804, sschott@biosite.com, both of Biosite Incorporated
|